Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced the international expansion of its medical aesthetics portfolio with the launch of its high-end aesthetic injection product, MaiLi, in Singapore. This marks another milestone in the company’s global foray into the medical aesthetics sector.
MaiLi is a premium sodium hyaluronate gel, also known as hyaluronic acid, developed by Kylane Laboratoires SA, a Swiss medical aesthetics firm in which Huadong Medicine holds a significant stake. The product received marketing approval from the European Union in June 2020 and was subsequently launched in the region during the first half of 2021. The MaiLi product line comprises MaiLi Precise, MaiLi Define, MaiLi Volume, and MaiLi Extreme, with the latter still awaiting regulatory approval in China.- Flcube.com
